Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181679 | 1.00 | TSHR (0.42) | TSHRHPGDTHRBALDH1A1TP53 | |
| SCHEMBL3966436 | 0.83 | TSHR (0.42) | TSHRHPGDTHRBALDH1A1TP53 | |
| SCHEMBL14775229 | 0.82 | TSHR (0.33) | TSHRHPGDALDH1A1 | |
| SCHEMBL3831873 | 0.80 | TSHR (0.41) | TSHRHPGDTHRBALDH1A1TP53 | |
| SCHEMBL4772452 | 0.80 | TSHR (0.51) | TSHRHPGDTHRBALDH1A1CYP3A4 | |
| SCHEMBL11806261 | 0.80 | — | — | |
| SCHEMBL8461805 | 0.80 | — | — | |
| SCHEMBL12314345 | 0.80 | — | — | |
| SCHEMBL7194659 | 0.80 | TSHR (0.41) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL1322363 | 0.79 | TSHR (0.44) | TSHRHPGDTHRBALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016179558-A1 | K-RAS MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2015196144-A2 | ANDROGEN RECEPTOR ANTAGONISTS | ENGLAND PAMELA M (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150175657-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2015-06-25 | — | — | US | disclosed |
| US-8722828-B2 | Process for continuous production of cycloolefin resins, and sheets or films thereof, using ring opening metathesis polymerization | ZEON CORPORATION (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8445498-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329901-B2 | 4,6-disubstitued pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120190614-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-1535941-A1 | PROCESSES FOR PRODUCING THERMOPLASTIC RESINS, CROSSLINKED RESINS AND CROSSLINKED RESIN COMPOSITE MATERIALS | ZEON CORPORATION (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1522501-A2 | Oriented cook-in film with good interply adhesion | Cryovac, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| US-6551674-B2 | Multilayer film | CRYOVAC, INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020015810-A1 | Oriented cook-in film with good interply adhesion | PIPER GRAHAM RICHARD (US) | 2002-02-07 | — | — | US | disclosed |
| EP-1173329-A1 | ORIENTED COOK-IN FILM WITH GOOD INTERPLY ADHESION | Cryovac, Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6294264-B1 | ATACTIC OR SYNDIOTACTIC PROPYLENE COPOLYMER; AND A SECOND LAYER COMPRISING A PROPYLENE/ALPHA-OLEFIN COPOLYMER; VICAT SOFTENING POINT OF AT LEAST 50 DEGREES C. | CRYOVAC, INC. | 2001-09-25 | — | — | US | disclosed |
| WO-2000058093-A1 | ORIENTED COOK-IN FILM WITH GOOD INTERPLY ADHESION | CRYOVAC, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| US-5280057-A | Polymer stabilizer | CIBA-GEIGY CORPORATION (US) | 1994-01-18 | — | — | US | disclosed |
| EP-0572569-A1 | WATER SOLUBLE ALCOHOL BASED NONWOVEN BINDER COMPOSITION. | FULLER H B LICENSING FINANC (US) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992015742-A2 | WATER SOLUBLE ALCOHOL BASED NONWOVEN BINDER COMPOSITION | H.B. FULLER LICENSING & FINANCING INC. (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190614-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | TSHR 4633/4885HPGD 2115/4885THRB 4623/4885 |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | TSHR 4633/4885HPGD 2115/4885THRB 4623/4885 |
| US-20150175657-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | TSHR 4633/4885HPGD 2115/4885THRB 4623/4885 |
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | TSHR 4020/4885HPGD 3481/4885THRB 2282/4885 |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TSHR 2837/4885HPGD 1580/4885THRB 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.